Three ADHD Brain “Biotypes”? Why Every Child’s Profile Is More Complex

Neuroscience headlines are compelling because they seem to promise something psychiatry rarely can: a visible answer.

For a parent whose child can concentrate for hours on a favorite project but cannot begin a short worksheet, or who craves stimulation yet becomes overwhelmed by change, the right “brain type” can feel like relief. Perhaps the contradictions finally fit.

That helps explain the attention given to National Geographic’s “There Might Be 3 Different Types of ADHD”, followed by a widely shared Washington Post article about three proposed ADHD brain “biotypes.” One of those groups was described as a severe combined presentation with prominent emotional dysregulation. The other two broadly resembled predominantly hyperactive/impulsive and predominantly inattentive presentations.

The research offers further evidence for something families and clinicians have long known: ADHD is heterogeneous. Two children can meet criteria for the same diagnosis while differing substantially in how they think, learn, regulate emotion, relate to others, and respond to demands.

But the most useful conclusion is not that every child with ADHD belongs in one of three new boxes. These are research-derived, group-level clusters, not validated diagnoses for individual patients. Nothing in this study shows that its MRI model can determine whether a child has ADHD, whether autism is also present, or which treatment will work best. The study does not make developmental history, school information, clinical judgment, or individualized assessment obsolete.

In fact, it points in the opposite direction. If ADHD is this varied at the level of brain organization, then a diagnosis should be the beginning of understanding a child, not the end.

The research suggests that ADHD’s heterogeneity has structure. It does not suggest that individuality stops at three.

What the New ADHD Biotype Study Actually Found

The study behind the headlines was published in JAMA Psychiatry by Pan and colleagues in February 2026. The researchers used structural MRI data to build what are called morphometric similarity networks. In simplified terms, they examined gray-matter volume distributions across 90 brain regions and calculated how structurally similar the regions were to one another. This is a mathematical measure of structural similarity, not a direct measurement of neural connections or moment-to-moment communication between regions.

The discovery dataset included 446 children with ADHD and 708 controls; a separate validation dataset included 554 children with ADHD and 123 controls. The procedure did not use symptom ratings to sort the ADHD cases. It began with MRI-derived patterns, then researchers examined clinical differences. The method was still semi-supervised because the model used the known distinction between ADHD cases and controls (Pan et al., 2026).

The researchers compared solutions containing two, three, or four ADHD clusters. Under the authors’ criteria, three was the preferred solution among those restricted options. That does not prove that nature contains exactly three exhaustive kinds of ADHD.

Three clusters emerged:

1. A severe combined cluster with emotional dysregulation. On average, this group showed the highest levels of both inattentive and hyperactive/impulsive symptoms. In a 73-person, single-site longitudinal subgroup, a broad rating-scale composite combining attention, aggression, and anxious/depressed symptoms declined less steeply over time in this group. The authors interpreted that pattern as more persistent difficulty with emotional self-regulation. Its MRI-derived pattern included broader alterations involving medial prefrontal and pallidal regions.
2. A predominantly hyperactive/impulsive cluster. On average, this group showed relatively greater hyperactivity and impulsivity, with differences centered more strongly in anterior cingulate and pallidal circuitry.
3. A predominantly inattentive cluster. On average, this group showed relatively greater inattention, with a pattern that more prominently involved the superior frontal gyrus.

The broad neural patterns were reproducible in the independent dataset, a meaningful strength. That brain-first clustering produced groups resembling recognizable clinical patterns suggests that some observed variation may correspond to underlying neurobiology.

Yet “resembled” matters. The groups did not divide into three perfectly separated natural kinds. Clinical differences between clusters were modest and overlapping. In the validation sample, the pattern for hyperactive/impulsive symptoms held, but the groups did not significantly differ in inattention. The study’s authors also note that the clusters may be points along continuous dimensions rather than three qualitatively distinct disorders.

A “Chemical Signature” Is Not Yet a Treatment Guide

The media descriptions of distinct chemical signatures deserve special care.

Researchers did not directly measure dopamine, serotonin, or other neurotransmitter systems in each participating child. They compared the spatial patterns derived from the children’s MRIs with receptor-density maps created from prior positron emission tomography research. Certain ADHD-cluster maps corresponded spatially with different receptor distributions.

That is scientifically interesting, but it is an indirect association. It does not show that a particular child has too much or too little of a given neurotransmitter. The authors explicitly state that these findings cannot establish actual receptor alterations in the participants or inform treatment selection (Pan et al., 2026).

The study did not assign or compare treatments by biotype. It cannot tell us that one cluster should receive a particular medication, that another will not benefit from stimulants, or that one therapy is best for the emotionally dysregulated cluster.

For now, medication decisions still depend on an individual child’s symptoms, health history, co-occurring conditions, prior responses, side effects, and careful monitoring with a qualified prescriber. A research cluster should not be used to bypass that process.

Why MRI Still Cannot Diagnose ADHD in an Individual Child

Brain-imaging studies have repeatedly found average structural and functional differences between groups of people with and without ADHD. Those findings help characterize ADHD-associated neurobiology at the group level. They do not provide a clinical scan that can diagnose a particular person.

The group-individual distinction is essential. Two neighborhoods can differ in average commute time without the neighborhood revealing how long one resident’s trip took this morning. The distributions overlap, and individual circumstances matter.

ADHD neuroimaging works similarly. Average differences are often small, there is extensive overlap between people with and without the diagnosis, and there is substantial variation within ADHD itself. The 2026 study found this overlap in its own data and described the challenge of identifying discrete biomarkers. Participants were right-handed youth ages 6 to 18 and predominantly boys. Race and ethnicity were not reported consistently, the samples were not uniformly medication-naive, and the exclusion of many co-occurring conditions limits direct generalization to the complex children typically seen in practice.

An ordinary clinical MRI is not processed through this study’s multisite research pipeline, normative modeling, and machine-learning procedures. Even if a model can assign a research participant to a statistical cluster, that does not establish that the assignment is sufficiently accurate, stable, and useful to guide real-world care. The World Federation of ADHD’s international consensus statement similarly concludes that observed imaging differences cannot currently be used to diagnose ADHD (Faraone et al., 2021).

MRI may be medically appropriate when a clinician is investigating a different neurological concern. That is separate from using a scan to confirm ADHD or choose ADHD treatment.

Emotional Dysregulation Deserves Attention Now

The new study is especially valuable for bringing emotional dysregulation into public discussion. It is not one of the core symptoms used to diagnose ADHD in the DSM-5-TR, and it is not present in every person with ADHD. Yet research has long shown that many children with ADHD have meaningful difficulty with emotional reactivity, lability, and regulation (Shaw et al., 2014; Graziano & Garcia, 2016).

For some children, frustration arrives and is expressed before they can pause. For others, the intensity or duration is most impairing. A small disappointment can trigger tears, shouting, flight, aggression, or prolonged withdrawal. The child may recognize afterward that the reaction was too large but be unable to access that perspective in the moment.

This should not automatically be read as manipulation, entitlement, or poor parenting. Comparisons to a “spoiled child” can obscure the clinical question: behavior is observable, but its mechanism must be investigated.

Emotional dysregulation is not specific to ADHD. Similar episodes can arise from anxiety, autism-related overload, depression or other mood concerns, trauma, chronic irritability, language difficulties, learning frustration, sleep loss, sensory distress, medication effects, or a mismatch between demands and a child’s developmental capacities. More than one factor may be operating at once.

The important questions are therefore more precise than “Does my child have the emotional ADHD type?”

• What tends to happen immediately before the reaction?
• Is the child responding to frustration, uncertainty, sensory input, a social misunderstanding, a difficult academic task, fatigue, or loss of control?
• How quickly does the reaction begin, and how long does recovery take?
• Does the same pattern occur at school, at home, with peers, and during preferred activities?
• What helps the child recover, and what reliably makes things worse?

These details can change the formulation and the plan even when the visible behavior looks the same.

ADHD Has More Than Three Clinically Relevant Profiles

A cluster is a useful research summary. A child is a multidimensional person.

Consider three students who all meet diagnostic criteria for ADHD. One reasons exceptionally well and contributes sophisticated ideas in class but has slow, effortful written output. Another reads below grade level and avoids homework because decoding is exhausting, while attention deteriorates as the text becomes harder. A third learns quickly and performs well in a quiet one-to-one setting but loses track of materials, misses deadlines, becomes overwhelmed by transitions, and falls apart after maintaining control through the school day.

Their ADHD label is relevant in each case. It is not sufficient to explain what each student needs.

An individualized formulation may need to consider:

• sustained attention and consistency over time;
• impulse control and response inhibition;
• task initiation, planning, organization, and time awareness;
• working memory and the ability to hold multiple steps in mind;
• cognitive flexibility and response to changes in plan;
• processing speed, output, and the cost of working efficiently;
• language, learning, and memory;
• reading, writing, and mathematics;
• emotional regulation, anxiety, mood, and frustration tolerance;
• social communication, sensory processing, and adaptive functioning;
• sleep, health, medication, stress, and environmental fit;
• interests, reasoning abilities, creativity, persistence, and other strengths.

These dimensions can combine in countless ways. Research reviews likewise find heterogeneity in ADHD’s causes, cognitive features, co-occurring conditions, brain findings, and developmental course (Luo et al., 2019). Meta-analytic work finds average ADHD-associated weaknesses across several cognitive domains (Pievsky & McGrath, 2018). Taken together with the broader heterogeneity literature, these are group patterns, not a single profile shared by everyone with ADHD.

This is why “three types” should not become a new online sorting exercise. A person may identify strongly with a cluster description without belonging to a validated clinical category. Another may have substantial ADHD-related impairment while looking unlike all three summaries.

Where AuDHD Fits, and Where It Does Not

The same caution applies to AuDHD, useful community shorthand for co-occurring autism and ADHD. Many people find that it captures an experience neither label describes fully on its own. The American Psychiatric Association also notes this use of AuDHD.

AuDHD is not a separate DSM-5-TR diagnosis, a brain biotype, or a conclusion to draw from an online trait list. DSM-5-TR permits both diagnoses when a person independently meets criteria for ADHD and autism; AuDHD is not a third combined disorder. Each condition still requires developmental and functional evidence. When both are plausible, evaluating ADHD and autism together can clarify what is shared, what is distinct, and what support is needed.

The apparent contradictions associated with AuDHD are real for many people. A child may rely on a predictable morning sequence, then become painfully bored by repetitive schoolwork. They may seek movement and novelty while becoming overloaded by noise and social unpredictability, or want friendships but need long recovery after a group.

These are not necessarily inconsistencies. Predictability and novelty can serve different functions. Routine may reduce uncertainty, transition demands, or sensory load. Novelty may increase alertness, interest, or reward. A child can need reliable structure around when and how something happens while needing choice and variation within that structure.

The clinical task is to understand the pattern, not merely name the paradox.

This is also where diagnostic overshadowing becomes a risk. Once ADHD is diagnosed, sensory overload, rigidity, or persistent social-communication differences may be explained away as distractibility or impulsivity. In one observational study, children who had received an ADHD diagnosis before autism were identified as autistic about 1.8 years later on average than children without a prior ADHD diagnosis. That association does not prove that ADHD caused the delay, but it illustrates the concern (Kentrou et al., 2019). Once autism is diagnosed, clinically significant inattention, disorganization, or hyperactivity may be treated as if it were simply part of autism. If emotional dysregulation is attributed automatically to either condition, anxiety, mood, trauma, sleep, language, or learning problems can be missed.

Careful assessment of co-occurring autism and ADHD therefore requires a developmental history, information across contexts, and attention to both shared and distinguishing features (Young et al., 2020). For children whose outward success may conceal the effort or distress underneath, our discussion of high-masking autism explores why no single behavior, questionnaire, or office interaction can answer the question.

What a Neuropsychological Evaluation Can Add

A neuropsychological evaluation is not a substitute brain scan, and it does not reveal a hidden ADHD biotype. It characterizes current cognitive and academic performance, then integrates those findings with history, records, ratings, observations, and context. That hypothesis-driven integration is central to neuropsychological assessment practice (American Academy of Clinical Neuropsychology, 2007).

Depending on the referral question, a comprehensive neuropsychological evaluation may include:

• developmental, medical, educational, and psychosocial history, plus relevant school records and prior evaluations;
• parent, teacher, and self-report measures across settings;
• direct assessment of reasoning, attention, executive functioning, working memory, processing speed, language, learning, memory, and academic skills;
• assessment of emotional, behavioral, social, and adaptive functioning, with observation of how the person approaches structure, difficulty, mistakes, fatigue, and feedback;
• differential diagnosis that considers ADHD alongside learning disorders, autism, anxiety, mood concerns, sleep problems, and other explanations.

No score is interpreted in isolation. A child may do well on a short, novel attention task in a quiet room yet have impairing ADHD during repetitive work, unstructured time, or a six-hour school day. Conversely, weak attention-test performance does not prove ADHD; anxiety, poor sleep, language demands, learning difficulty, and other factors can reduce performance.

The American Academy of Pediatrics notes that neuropsychological testing has not been found to improve ADHD diagnostic accuracy in most cases, although it can clarify learning strengths and weaknesses (Wolraich et al., 2019). The point is to use testing for the right questions.

If the only question is whether an otherwise uncomplicated symptom pattern meets ADHD criteria, a high-quality focused ADHD evaluation may be sufficient. Broader testing is more useful when a family needs to understand inconsistent functioning, interacting conditions, partial treatment response, or which educational and clinical supports fit the person’s profile.

The goal is not a larger pile of scores but a coherent explanation. A good report can help distinguish a child who understands material but cannot organize an answer from one with weak foundational skills or anxiety that consumes working memory. It should also identify strengths that can support weaker areas.

Parents using pediatric neuropsychological services often report gaining knowledge, and informal home and school strategies are implemented more often than other recommendations. Outcomes research remains limited, and testing itself is not treatment (Fisher et al., 2022). Value depends on translating findings into a prioritized, practical plan.

For a student, that plan might address explicit academic intervention, executive-function support, environmental structure, emotional-regulation treatment, classroom accommodations, or further medical consultation. In New York City, children carrying the same ADHD diagnosis may need very different combinations of specialized instruction, school-based support, outside treatment, and accommodations. A clinical diagnosis can be important, but it does not automatically determine an IEP, Section 504 Plan, particular service, accommodation, or placement. IDEA and Section 504 require individualized educational decision-making based on evaluation data and functional need (34 C.F.R. § 300.306; U.S. Department of Education, Office for Civil Rights, n.d., FAQs 22–24, 27).

When a Broader Evaluation May Be Worth Considering

Not every child with ADHD needs comprehensive neuropsychological testing. Monitoring, a focused clinical assessment, treatment, or targeted school intervention may be the more proportionate next step.

A broader evaluation may be especially useful when:

• strong abilities and acceptable grades appear to conceal excessive time, support, or distress;
• parent and teacher descriptions seem irreconcilable;
• attention problems overlap with reading, writing, math, language, memory, or processing concerns;
• emotional outbursts, rigidity, sensory distress, or social differences raise questions beyond ADHD;
• a child has made limited progress despite reasonable intervention or treatment;
• several diagnoses have accumulated without a clear explanation of how they fit together;
• the family or school needs specific, function-based recommendations rather than another label.

An ability-performance mismatch is a reason to investigate, not proof of ADHD or a learning disability. Every piece of evidence has to be interpreted within the larger pattern.

What Parents Can Take From the Three-Biotype Headlines

Parents do not need to dismiss the new research, and they do not need to wait for clinical brain typing to benefit from its central insight.

First, take emotional regulation seriously. Track triggers, intensity, duration, recovery, and what helps. Bring those observations to the child’s clinician rather than treating emotional episodes as an embarrassing side issue.

Second, ask what else has been considered. If ADHD explains only part of the picture, a clinician should consider learning, language, anxiety, mood, autism, sleep, medical factors, and environmental demands. This does not mean searching endlessly for diagnoses. It means testing plausible explanations before forcing every difficulty under one familiar label.

Third, ask what information would change the plan. Testing is most useful when it answers a consequential question. Would the result alter treatment, instruction, accommodations, school supports, or the way adults respond to the child?

Fourth, be cautious about services claiming that an MRI, computerized attention test, or proprietary “brain map” can definitively diagnose ADHD or select the right medication. Research tools can be promising without being ready for individual clinical use (Faraone et al., 2021; Pan et al., 2026; Wolraich et al., 2019).

Finally, remember that support can begin before every diagnostic question is settled. A child who needs clearer transitions, reduced overload, explicit academic instruction, movement, sleep treatment, or help recovering from frustration does not need to wait for a future biomarker.

The Most Important Finding Is Complexity

The three-biotype study should not be reduced to a claim that scientists have discovered three definitive kinds of ADHD. Its more durable contribution is the evidence that a familiar diagnosis can contain meaningfully different clinical and neurobiological patterns.

That message is validating. It is consistent with families’ observation that the same strategy may help one child and not another, that two people with ADHD may barely recognize themselves in each other, and that emotional dysregulation deserves careful clinical attention.

It also argues for humility. No brain image, checklist, test score, or online identity label can replace the work of understanding the whole person. The most useful question is not simply, “Which type is my child?” It is, “What combination of strengths, vulnerabilities, experiences, and demands best explains how this child is functioning, and what will genuinely help?”

When ADHD, autism, learning, executive functioning, and emotional concerns overlap, an individualized assessment can help organize those questions into a coherent profile. Families can contact NYC Neurobehavioral Health to discuss whether consultation, a focused assessment, or a broader evaluation is the most appropriate next step.

This article provides general educational information and is not a substitute for individualized medical, psychological, or educational advice.

Research and Clinical Sources

American Academy of Clinical Neuropsychology. (2007). American Academy of Clinical Neuropsychology practice guidelines for neuropsychological assessment and consultation. The Clinical Neuropsychologist, 21(2), 209–231. https://doi.org/10.1080/13825580601025932

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787

American Psychiatric Association. (2025, July 17). When autism and ADHD occur together. https://www.psychiatry.org/news-room/apa-blogs/when-autism-and-adhd-occur-together

Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., Rohde, L. A., Yang, L., Cortese, S., Almagor, D., Stein, M. A., Albatti, T. H., Aljoudi, H. F., Alqahtani, M. M. J., Asherson, P., . . . Wang, Y. (2021). The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience & Biobehavioral Reviews, 128, 789–818. https://doi.org/10.1016/j.neubiorev.2021.01.022

Fisher, E. L., Zimak, E., Sherwood, A. R., & Elias, J. (2022). Outcomes of pediatric neuropsychological services: A systematic review. The Clinical Neuropsychologist, 36(6), 1265–1289. https://doi.org/10.1080/13854046.2020.1853812

Graziano, P. A., & Garcia, A. (2016). Attention-deficit hyperactivity disorder and children’s emotion dysregulation: A meta-analysis. Clinical Psychology Review, 46, 106–123. https://doi.org/10.1016/j.cpr.2016.04.011

Kentrou, V., de Veld, D. M. J., Mataw, K. J. K., & Begeer, S. (2019). Delayed autism spectrum disorder recognition in children and adolescents previously diagnosed with attention-deficit/hyperactivity disorder. Autism, 23(4), 1065–1072. https://doi.org/10.1177/1362361318785171

Luo, Y., Weibman, D., Halperin, J. M., & Li, X. (2019). A review of heterogeneity in attention deficit/hyperactivity disorder (ADHD). Frontiers in Human Neuroscience, 13, Article 42. https://doi.org/10.3389/fnhum.2019.00042

Pan, N., Long, Y., Qin, K., Pope, I. Z., Chen, Q., Zhu, Z., Cao, Y., Li, L., Singh, M. K., McNamara, R. K., DelBello, M. P., Chen, Y., Fornito, A., & Gong, Q. (2026). Mapping ADHD heterogeneity and biotypes by topological deviations in morphometric similarity networks. JAMA Psychiatry, 83(5), 478–490. https://doi.org/10.1001/jamapsychiatry.2026.0001

Pievsky, M. A., & McGrath, R. E. (2018). The neurocognitive profile of attention-deficit/hyperactivity disorder: A review of meta-analyses. Archives of Clinical Neuropsychology, 33(2), 143–157. https://doi.org/10.1093/arclin/acx055

Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014). Emotion dysregulation in attention deficit hyperactivity disorder. American Journal of Psychiatry, 171(3), 276–293. https://doi.org/10.1176/appi.ajp.2013.13070966

Wolraich, M. L., Hagan, J. F., Jr., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., Holbrook, J. R., Lehmann, C. U., Lessin, H. R., Okechukwu, K., Pierce, K. L., Winner, J. D., Zurhellen, W., & Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528. https://doi.org/10.1542/peds.2019-2528

Young, S., Hollingdale, J., Absoud, M., Bolton, P., Branney, P., Colley, W., Craze, E., Dave, M., Deeley, Q., Farrag, E., Gudjonsson, G., Hill, P., Liang, H.-L., Murphy, C., Mackintosh, P., Murin, M., O’Regan, F., Ougrin, D., Rios, P., . . . Woodhouse, E. (2020). Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus. BMC Medicine, 18, Article 146. https://doi.org/10.1186/s12916-020-01585-y

Legal and Regulatory Sources

34 C.F.R. § 300.306. Determination of eligibility. U.S. Department of Education, Individuals with Disabilities Education Act. https://sites.ed.gov/idea/regs/b/d/300.306

U.S. Department of Education, Office for Civil Rights. (n.d.). Frequently asked questions: Section 504 free appropriate public education (FAPE). https://www.ed.gov/laws-and-policy/civil-rights-laws/disability-discrimination/frequently-asked-questions-section-504-free-appropriate-public-education-fape